Celldex begins Phase I/II trial of CDX-014 to treat RCC
US-based Celldex Therapeutics has begun the Phase I/II study of CDX-014, a new antibody-drug conjugate (ADC) to treat renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - July 13, 2016 Category: Pharmaceuticals Source Type: news

Pfizer reports positive top-line result of Phase III S-TRAC Trial of Sutent to treat RCC
US-based pharmaceutical company Pfizer has reported positive top-line results of the Phase III S-TRAC clinical trial of Sutent against placebo to treat patients with renal cell carcinoma (RCC) who are at high risk for recurrence after surgery. (Source: Drug Development Technology)
Source: Drug Development Technology - July 11, 2016 Category: Pharmaceuticals Source Type: news

Various miRNAs predict the effect of anti-angiogenic agents on renal cancer
(Centro Nacional de Investigaciones Oncológicas (CNIO)) CNIO researchers have come across various potential predictive biomarkers of tyrosine kinase inhibitors (TKI) -- a type of anti-angiogenic agent widely used -- response in metastatic renal cancer. In their study, published in JCI Insight, the researchers identify various miRNAs that define a group of patients with the poorest response to TKI treatment and with the worst prognosis. The study, conducted on 139 patient samples, is the most robust to date in renal cell carcinoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 7, 2016 Category: Cancer & Oncology Source Type: news

New Study: Asbestos Related to Most Common Kidney Cancer
Exposure to asbestos may lead to renal cell carcinoma, the most common type of kidney cancer, an Italian study shows. The link to kidney cancer adds to the horrific history of asbestos, a substance definitively recognized as a cause of mesothelioma, lung cancer and a variety of other respiratory illnesses. In the past, a handful of other cancers were inconclusively linked to asbestos exposure. However, the research team at the University of Pavia in Italy made its case for asbestos as a probable cause of renal cell carcinoma. “The findings did surprise me. It was something I had not suspected before,” Stefano C...
Source: Asbestos and Mesothelioma News - July 1, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: asbestos cancer asbestos related to kidney cancer cancer research mesothelioma peritoneal mesothelioma Source Type: news

CCF/KCA Young Investigator Awards
Conquer Cancer Foundation/Kidney Cancer Association Young Investigator Award Recipients   Henk Verheul, MD, PhD “Combination antiangiogenesis and anticoagulatory therapy in patients with advanced renal cell cancer” 2006 Young Investigator Award   Patricia Tang, MD “The Role of VEGF-A Signaling in Maintenance of the Glomerular Filtration Barrier and Blood Pressure” 2007 Young Investigator Award   Aymen Elfiky, MD “Targeting Phosphoinositide 3-kinase in Renal Cell Cancer” 2008 Young Investigator Award   Kevin Courtney, MD, PhD “Identification of act...
Source: Kidney Cancer Association - June 30, 2016 Category: Urology & Nephrology Source Type: news

CCF/KCA Young Investigator Awards
Conquer Cancer Foundation/Kidney Cancer Association Young Investigator Award Recipients Henk Verheul, MD, PhD“Combination antiangiogenesis and anticoagulatory therapy in patients with advanced renal cell cancer”2006 Young Investigator Award Patricia Tang, MD“The Role of VEGF-A Signaling in Maintenance of the Glomerular Filtration Barrier and Blood Pressure”2007 Young Investigator Award Aymen Elfiky, MD“Targeting Phosphoinositide 3-kinase in Renal Cell Cancer”2008 Young Investigator Award Kevin Courtney, MD, PhD“Identification of activators of phosphoinositide 3-...
Source: Kidney Cancer Association - June 30, 2016 Category: Urology & Nephrology Source Type: news

Finding a niche for girentuximab in metastatic renal cell carcinoma
A small phase II study highlights modest efficacy and a concerning safety profile associated with this compound in patients with metastatic RCC.06/29/2016 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 29, 2016 Category: Urology & Nephrology Source Type: news

Renal Cell Carcinoma
Title: Renal Cell CarcinomaCategory: Doctor's & Expert's views on SymptomsCreated: 6/29/2016 12:00:00 AMLast Editorial Review: 6/29/2016 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - June 29, 2016 Category: Cancer & Oncology Source Type: news

Cabozantinib a Possible New Standard in Second-line Metastatic RCCCabozantinib a Possible New Standard in Second-line Metastatic RCC
Dr David Graham reviews the METEOR trial in metastatic renal cell carcinoma, one of the most important studies on genitourinary malignancies presented at ASCO 2016. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 21, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Cabozantinib extends advanced RCC overall survival
Patients with advanced or metastatic renal cell carcinoma derive a significant overall survival benefit from second-line treatment with the multi-tyrosine kinase inhibitor cabozantinib relative to everolimus. (Source: MedWire News)
Source: MedWire News - June 17, 2016 Category: Consumer Health News Tags: Kidney cancer Source Type: news

Exelixis and Ipsen report positive Phase III Meteor trial data of Cabometyx tablets
Exelixis and Ipsen have announced positive subgroup analyses of the Phase III Meteor trial data of Cabometyx (cabozantinib) tablets to treat advanced renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - June 8, 2016 Category: Pharmaceuticals Source Type: news

Novartis and Eisai to promote Lenvima in combination with everolimus to treat RCC
Switzerland’s Novartis Pharmaceuticals has entered into an agreement with Japanese firm Eisai’s US subsidiary to co-promote Lenvima (lenvatinib) capsules in combination with everolimus, to treat patients with advanced renal cell carcinoma (RCC) follo… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - June 6, 2016 Category: Pharmaceuticals Source Type: news

Report: Opdivo set to have biggest share in renal cell carcinoma market by 2023
Opdivo is projected to lead the growth in renal cell carcinoma (RCC) market and be a market leader by 2023, according to a report by GlobalData. (Source: Drug Development Technology)
Source: Drug Development Technology - June 3, 2016 Category: Pharmaceuticals Source Type: news

Cabometyx (cabozantinib) for Treatment of Patients with Advanced Renal Cell Carcinoma
Cabometyx (cabozantinib), developed by Exelixis, is used for treatment of patients with advanced renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - June 1, 2016 Category: Pharmaceuticals Source Type: news

What to Watch for in Genitourinary CancersWhat to Watch for in Genitourinary Cancers
This year's ASCO annual meeting will feature important developments in bladder cancer, renal cell carcinoma, and prostate cancer. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 27, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Aveo Oncology starts dosing in Phase lll trial of tivozanib and sorafenib to treat RCC
US-based biopharmaceutical company Aveo Oncology (Aveo) has started dosing in a Phase lll randomised, controlled, multi-centre, open-label trial (TIVO-3) to compare tivozanib with sorafenib in patients with refractory advanced renal cell carcinoma (R… (Source: Drug Development Technology)
Source: Drug Development Technology - May 27, 2016 Category: Pharmaceuticals Source Type: news

Exelixis’ Phase ll trial finds cabozantinib better than sunitinib in treating RCC
US-based biopharmaceutical company Exelixis has demonstrated improvement in progression-free survival (PFS) with cabozantinib, compared to sunitinib in patients with advanced intermediate or poor risk renal cell carcinoma (RCC) during Phase ll trial … (Source: Drug Development Technology)
Source: Drug Development Technology - May 25, 2016 Category: Pharmaceuticals Source Type: news

FDA Approves Lenvatinib) for Treatment of mRCC
U.S. Food and Drug Administration (FDA) approved Lenvima (lenvatinib, in combination with everolimus for the treatment of patients with advanced renal cell carcinoma...05/16/2016 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 24, 2016 Category: Urology & Nephrology Source Type: news

Eisai's Lenvima receives FDA approval for new indication
Eisai has received approval from the US Food and Drug Administration (FDA) for a new indication of its anticancer agent, Lenvima (lenvatinib mesylate), as a treatment for advanced renal cell carcinoma. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 17, 2016 Category: Pharmaceuticals Source Type: news

FDA Approves Lenvima (lenvatinib) for the Treatment of Advanced Renal Cell Carcinoma
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Lenvima (lenvatinib), the company's multiple receptor tyrosine kinase inhibitor, in combination with everolimus for the treatment of patients with advanced renal cell carcinoma (aRCC) who were previously treated with an anti-angiogenic therapy. This approval was based on the impressive results of the registration study (Study 205), in which the once daily combination of 18 mg Lenvima and 5 mg everolimus demonstrated a substantial improvement in progression-free survival (PFS), powerful objective response rate (ORR) and clinically meaningfu...
Source: Kidney Cancer Association - May 16, 2016 Category: Urology & Nephrology Source Type: news

FDA Approves Lenvatinib for Advanced Renal Cell CarcinomaFDA Approves Lenvatinib for Advanced Renal Cell Carcinoma
The drug is to be used in combination with everolimus, and improves progression-free survival, overall response rate, and overall survival compared with everolimus alone. FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 14, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Lenvima (lenvatinib) for the Treatment of Patients with Advanced Renal Cell Carcinoma in Combination with Everolimus Following Prior Anti-Angiogenic Therapy
WOODCLIFF LAKE, N.J., May 13, 2016 /PRNewswire/ -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Lenvima (lenvatinib), the company's multiple receptor tyrosine kinase inhibitor, in combination with everolimus... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 13, 2016 Category: Drugs & Pharmacology Source Type: news

FDA Approves Lenvima (lenvatinib) for the Treatment of Patients with Advanced Renal Cell Carcinoma
WOODCLIFF LAKE, N.J., May 13, 2016 /PRNewswire/ -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Lenvima (lenvatinib), the company's multiple receptor tyrosine kinase inhibitor, in combination with everolimus... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 13, 2016 Category: Drugs & Pharmacology Source Type: news

First Patient Dosed In Phase 1/2 Trial Evaluating CRLX101 In Combination With LYNPARZA
The U.S. FDA has granted CRLX101 Orphan Drug designation for the treatment of ovarian cancer and Fast Track designation in combination with Avastin® in metastatic renal cell carcinoma.05/11/2016 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 11, 2016 Category: Urology & Nephrology Source Type: news

X4 Pharmaceuticals begins dosing in Phase l/ll study of X4P-001 to treat advanced ccRCC
US-based, clinical stage, biotechnology company X4 Pharmaceuticals has dosed its first patient in a Phase l/ll trial of X4P-001, the company’s lead CXCR4 inhibitor, to treat patients with advanced clear cell renal cell carcinoma (ccRCC). (Source: Drug Development Technology)
Source: Drug Development Technology - May 11, 2016 Category: Pharmaceuticals Source Type: news

No Increased Toxicity Seen With TKI, Stereotactic Radiosurgery No Increased Toxicity Seen With TKI, Stereotactic Radiosurgery
TKIs used as radiosensitizers are believed to offer a synergistic effect with radiosurgery in treatment of spine metastases with renal cell carcinoma. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - May 6, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Report: Renal cell carcinoma to be a $3.6bn market by 2023
A GlobalData report has revealed that the major markets of the US, the UK, France, Germany, Italy, Spain, Japan and China will lead the growth in renal cell carcinoma (RCC) from $2.1bn in 2013 to $3.6bn by 2023. (Source: Drug Development Technology)
Source: Drug Development Technology - April 29, 2016 Category: Pharmaceuticals Source Type: news

FDA Approves Cabozantinib for Renal Cell CarcinomaFDA Approves Cabozantinib for Renal Cell Carcinoma
As a second-line therapy for advanced disease, it has recently been shown to improve survival. But is it a better choice than nivolumab? FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 26, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Exelixis Announces FDA Approval of Cabometyx (cabozantinib) for Patients with Advanced Renal Cell Carcinoma
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr. 25, 2016-- Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved Cabometyx (cabozantinib) tablets for the treatment of patients with advanced... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 26, 2016 Category: Drugs & Pharmacology Source Type: news

FDA Approves CABOMETYX™ (Cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma
CABOMETYX, which was granted Fast Track and Breakthrough Therapy designations by the FDA, is the first therapy to demonstrate in a phase 3 trial for patients with advanced RCC, robust and clinically meaningful improvements in all three key efficacy parameters...04/25/2016 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 25, 2016 Category: Urology & Nephrology Source Type: news

FDA Approves CABOMETYX ™ (Cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma
CABOMETYX, which was granted Fast Track and Breakthrough Therapy designations by the FDA, is the first therapy to demonstrate in a phase 3 trial for patients with advanced RCC, robust and clinically meaningful improvements in all three key efficacy parameters... 04/25/2016 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 25, 2016 Category: Urology & Nephrology Source Type: news

Lenvatinib in Renal Cell Carcinoma
"...it produced a 43% response rate, a PFS in the 14- or 15-month range, and a 25-month median OS. I think it’s impressive."04/23/2016 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 23, 2016 Category: Urology & Nephrology Source Type: news

Discovery of a novel target for renal cell carcinoma
We recently reported that monotherapy using the TGase 2 inhibitor GK921 in a xenograft tumor model abrogated RCC growth through p53 stabilization.04/22/2016 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 22, 2016 Category: Urology & Nephrology Source Type: news

Link between obesity, kidney cancer identified
Receptors for leptin, a protein hormone, may be associated with tumor recurrence in patients with renal cell carcinoma (RCC), providing further understanding about molecular links between obesity and RCC tumor formation and prognosis, according to a study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 13, 2016 Category: Science Source Type: news

Study suggests link between obesity and kidney cancer
(University of Texas M. D. Anderson Cancer Center) Receptors for leptin, a protein hormone, may be associated with tumor recurrence in patients with renal cell carcinoma (RCC), providing further understanding about molecular links between obesity and RCC tumor formation and prognosis, according to a study at The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 13, 2016 Category: Cancer & Oncology Source Type: news

For RCC, VEGFR-TKIs Safe, Effective After PD-1 Inhibitors
Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) are safe and effective after treatment with a programmed cell death 1 (PD-1) inhibitor in patients with metastatic renal cell carcinoma...04/09/2016 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 9, 2016 Category: Urology & Nephrology Source Type: news

Stimulating IL-2/Anti-IL-2 Antibody Complexes in RCCStimulating IL-2/Anti-IL-2 Antibody Complexes in RCC
This study examines the possible beneficial effects. BMC Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 8, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

EC grants approval for Bristol-Myers' Opdivo to treat renal cell carcinoma
Bristol-Myers Squibb has obtained approval from the European Commission (EC) for its Opdivo (nivolumab) for previously treated advanced renal cell carcinoma (RCC). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - April 8, 2016 Category: Pharmaceuticals Source Type: news

EU Expands Nivolumab Approval For Lung and Kidney CancerEU Expands Nivolumab Approval For Lung and Kidney Cancer
Nivolumab is now approved in Europe for both nonsquamous- and squamous-type non-small-cell lung cancer, as well as for use in renal cell carcinoma. International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 6, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Genomic clue to ethnic disparities in clear cell RCC survival
medwireNews: The poorer survival outcomes for African–American versus White patients with clear cell renal cell carcinoma (RCC) could be explained by inherent differences in tumour genomics, indicate ... (Source: MedWire News)
Source: MedWire News - March 31, 2016 Category: Consumer Health News Tags: Kidney cancer Source Type: news

Patients Needed for Research Project
A major pharmaceutical manufacturer has commissioned market research to help improve its communications directed toward Renal Cell Carcinoma (RCC) patients. Your participation in this research project can help ensure that the company’s website and other materials are relevant to patients’ concerns and expressed in a clear and comprehensible way. Flince Research + Design, an independent healthcare research and consulting firm located in the U.S., has been engaged to conduct these research interviews on pharmaceutical manufacturer’s behalf.   The research proje...
Source: Kidney Cancer Association - March 15, 2016 Category: Urology & Nephrology Source Type: news

Patients Needed for Research Project
A major pharmaceutical manufacturer has commissioned market research to help improve its communications directed toward Renal Cell Carcinoma (RCC) patients.Your participation in this research project can help ensure that the company’s website and other materials are relevant to patients’ concerns and expressed in a clear and comprehensible way.Flince Research + Design, an independent healthcare research and consulting firm located in the U.S., has been engaged to conduct these research interviews on pharmaceutical manufacturer’s behalf.   The research project&n...
Source: Kidney Cancer Association - March 15, 2016 Category: Urology & Nephrology Source Type: news

Largest genomic study on kidney cancer brings hope for more effective treatments
A comprehensive molecular analysis of 894 primary renal cell carcinomas resulted in nine subtypes defined by systematic analysis of five genomic data platforms. Each major histologic types represent substantial molecular diversity.03/15/2016 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 15, 2016 Category: Urology & Nephrology Source Type: news

Core-Needle Biopsy Leads to 94% Accurate Renal Carcinoma Diagnosis
Adding core-needle biopsy to other clinical care may help improve outcomes for some patients with renal cell carcinoma...03/12/2016 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 12, 2016 Category: Urology & Nephrology Source Type: news

Renal cell carcinoma: Therapy change can significantly improve treatment result
A research team was able to demonstrate that a therapy change in the area of metastasizing renal cell carcinoma significantly increases the life average expectancy and clearly improves the compatibility of the therapy. The extent of the influence of the administration rhythm of Sunitinib, an effective ingredient which is utilised in the target-oriented therapy, on the treatment results was examined. The result: In 71% of the patients, the therapy change resulted in an average survival extension of 33 months to approximately 75 months. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 8, 2016 Category: Science Source Type: news

EU Panel Likes Nivolumab for Kidney Cancer, Other DrugsEU Panel Likes Nivolumab for Kidney Cancer, Other Drugs
A European advisory committee has recommended extending the indication for immunotherapy to include the treatment of advanced renal cell carcinoma. News Alerts (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 26, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

H3K36me3 and Risk of Renal Cell Carcinoma-Specific DeathH3K36me3 and Risk of Renal Cell Carcinoma-Specific Death
This study suggests H3K36me3 expression may be useful as a prognostic biomarker post-nephrectomy for clear cell renal carcinoma. Modern Pathology (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - February 18, 2016 Category: Pathology Tags: Pathology & Lab Medicine Journal Article Source Type: news

Design and characterization of the tumor vaccine MGN1601
The tumor vaccine MGN1601 was designed and developed for treatment of metastatic renal cell carcinoma (mRCC). MGN1601 consists of a combination of fourfold gene-modified cells with the toll-like receptor 9 agonist dSLIM, a powerful connector of innate and adaptive immunity.02/11/2016 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 11, 2016 Category: Urology & Nephrology Source Type: news